Title: Allicin as an add-on treatment in acute exacerbation of bronchiectasis: a clinical study
Abstract: Objective
To investigate the clinical efficacy of allicin in the treatment of acute exacerbation of bronchiectasis.
Methods
Included in this study were 120 patients with acute exacerbation of bronchiectasis admitted to our hospital between October 2015 and October 2017. Using a random number table, the patients were assigned to a control group (n=60) or a study group (n=60) . The control group received routine treatment, while the study group received oral allicin in addition to the routine treatment. Before and at 1 week after treatment, inflammatory biomarkers in the two groups were examined, including serum C-reactive protein (CRP) , procalcitonin (PCT) , and neutrophil percentage (N%) . At 1 week after treatment, the clinical efficacy was evaluated and the occurrence of treatment-related adverse reactions was recorded.
Results
After treatment, serum levels of CRP and PCT, and N% were significantly lowered in the both groups from baseline (all P<0.05) . Compared with the control group, the post-treatment serum levels of CRP and PCT, and N% in the study group were significantly lower (all P<0.05) . The effective rates of treatment in the study group vs the control group were 66.7% (40/60) vs 58.3% (35/60) , with no significant difference between two groups (χ2=0.889, P=0.346) . Gastrointestinal reactions occurred in 3 patients in the study group, and they all resolved after discontinuation of allicin. There were no obvious adverse reactions in the control group.
Conclusion
Allicin as an add-on treatment may be beneficial for patients with acute exacerbation of bronchiectasis with modest adverse reactions.
Key words:
Allicin; Bronchiectasis; Treatment outcome; Adverse effects
Publication Year: 2017
Publication Date: 2017-12-15
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot